ATE446366T1 - Agonistische monoklonale antikörper gegen trkc - Google Patents

Agonistische monoklonale antikörper gegen trkc

Info

Publication number
ATE446366T1
ATE446366T1 AT01950429T AT01950429T ATE446366T1 AT E446366 T1 ATE446366 T1 AT E446366T1 AT 01950429 T AT01950429 T AT 01950429T AT 01950429 T AT01950429 T AT 01950429T AT E446366 T1 ATE446366 T1 AT E446366T1
Authority
AT
Austria
Prior art keywords
monoclonal antibodies
trkc
antibodies against
agonistic monoclonal
antibodies
Prior art date
Application number
AT01950429T
Other languages
English (en)
Inventor
Brigitte Devaux
Jo-Anne Hongo
Leonard Presta
David Shelton
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE446366T1 publication Critical patent/ATE446366T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT01950429T 2000-06-22 2001-06-22 Agonistische monoklonale antikörper gegen trkc ATE446366T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21314100P 2000-06-22 2000-06-22
US23831900P 2000-10-05 2000-10-05
PCT/US2001/020153 WO2001098361A2 (en) 2000-06-22 2001-06-22 Agonist anti-trk-c monoclonal antibodies

Publications (1)

Publication Number Publication Date
ATE446366T1 true ATE446366T1 (de) 2009-11-15

Family

ID=26907807

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01950429T ATE446366T1 (de) 2000-06-22 2001-06-22 Agonistische monoklonale antikörper gegen trkc

Country Status (17)

Country Link
US (4) US7384632B2 (de)
EP (1) EP1292680B1 (de)
JP (1) JP2004500873A (de)
KR (1) KR100823764B1 (de)
CN (1) CN100519749C (de)
AT (1) ATE446366T1 (de)
AU (2) AU7142201A (de)
BR (1) BR0112272A (de)
CA (1) CA2412494C (de)
DE (1) DE60140252D1 (de)
DK (1) DK1292680T3 (de)
HU (1) HU228310B1 (de)
IL (2) IL153375A0 (de)
MX (1) MXPA02012602A (de)
NZ (1) NZ523105A (de)
PL (1) PL208113B1 (de)
WO (1) WO2001098361A2 (de)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5877016A (en) * 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
EP2230253B1 (de) 2000-06-05 2013-08-07 The Brigham & Women's Hospital, Inc. Antikörper gegen ein Homolog des humanen MDR-P-Glycoproteins auf Chromosom 7p15-21 und deren Verwendungen
DK1292680T3 (da) * 2000-06-22 2010-03-08 Genentech Inc Agonist-anti-TrkC monoklonale antistoffer
GB0210783D0 (en) * 2002-05-10 2002-06-19 Polonelli Luciano Anti-microbial polypeptides
AU2003298112A1 (en) * 2002-11-13 2004-06-03 Micromet Ag Method for identifying antigen specific b cells
AU2003300397A1 (en) * 2002-12-23 2004-07-22 Rinat Neuroscience Corp. Methods for treating taxol-induced sensory neuropathy
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
WO2004084836A2 (en) * 2003-03-20 2004-10-07 Rinat Neuroscience Corp. Methods for treating taxol-induced gut disorder
CA2551097A1 (en) * 2003-12-23 2005-07-14 Rinat Neuroscience Corp. Agonist anti-trkc antibodies and methods using same
AR054260A1 (es) * 2005-04-26 2007-06-13 Rinat Neuroscience Corp Metodos de tratamiento de enfermedades de la neurona motora inferior y composiciones utilizadas en los mismos
MX2007015292A (es) * 2005-06-06 2008-02-21 Wyeth Corp Anticuerpos monoclonales anti-trkb y sus usos.
CN103145840A (zh) * 2005-06-30 2013-06-12 Abbvie公司 Il-12/p40结合蛋白
RU2442793C2 (ru) 2005-11-30 2012-02-20 Эбботт Лэборетриз АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ
CN101506236B (zh) 2005-11-30 2012-12-12 雅培制药有限公司 抗淀粉样β蛋白的单克隆抗体及其用途
CA2637826A1 (en) 2006-02-02 2007-08-09 Rinat Neuroscience Corporation Methods for treating unwanted weight loss or eating disorders by administering a trkb agonist
PL2035549T3 (pl) 2006-05-31 2014-12-31 Childrens Medical Center ABCB5-dodatnie mezenchymalne komórki macierzyste jako immunomodulatory
US8455626B2 (en) * 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US8648169B2 (en) * 2006-12-05 2014-02-11 The Royal Institution For The Advancement Of Learning/Mcgill University Methods of use of Trk receptor modulators
HRP20140049T1 (hr) 2007-01-05 2014-02-28 University Of Zürich Anti beta-amiloid antitijela i njihova upotreba
EP2124952A2 (de) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Verfahren zur behandlung von amyloidosen
CA2718573C (en) 2007-04-12 2020-07-14 The Brigham And Women's Hospital, Inc. Targeting abcb5 for cancer therapy
US8168757B2 (en) * 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
CA2724830A1 (en) * 2008-05-21 2009-11-26 Centre Leon Berard Inhibition of the nt-3:trkc bound and its application to the treatment of cancer such as neuroblastoma
EP2350075B1 (de) 2008-09-22 2014-03-05 Array Biopharma, Inc. Substituierte imidazo[1,2b]pyridazinverbindungen als trk-kinase-inhibitoren
KR101853026B1 (ko) 2008-10-22 2018-04-27 어레이 바이오파마 인크. ＴＲＫ 키나아제 억제제로서 치환된 피라졸로［１,５­ａ］ 피리미딘 화합물
ES2796111T3 (es) 2008-11-14 2020-11-25 Brigham & Womens Hospital Inc Métodos terapéuticos relacionados con células madre cancerosas
US11542328B2 (en) 2008-11-14 2023-01-03 The Brigham And Women's Hospital, Inc. Therapeutic and diagnostic methods relating to cancer stem cells
CA2746778C (en) 2008-12-19 2019-04-23 University Of Zurich Human anti-alpha-synuclein autoantibodies
US20100272640A1 (en) 2009-04-24 2010-10-28 Ozge Alper Monoclonal Antibodies Against PCBP-1 Antigens, and Uses Therefor
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
CN102574924A (zh) * 2009-09-03 2012-07-11 先灵公司 抗-gitr抗体
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
CN105693720B (zh) 2010-05-20 2019-01-18 阵列生物制药公司 作为trk激酶抑制剂的大环化合物
KR20130048240A (ko) 2010-07-14 2013-05-09 알퍼 바이오테크, 엘엘씨 Ｐｃｂｐ―１ 항원에 대한 모노클로날 항체, 및 그의 용도
CN103298833B (zh) 2010-08-14 2015-12-16 Abbvie公司 β淀粉样蛋白结合蛋白
WO2012027821A1 (en) * 2010-09-03 2012-03-08 The Royal Institution For The Advancement Of Learning / Mcgill University A trkc receptor agonist antibody to treat neurodegenerative and motor neuron diseases
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
NZ611076A (en) 2010-12-01 2015-09-25 Alderbio Holdings Llc Anti-ngf compositions and use thereof
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
CA2830503A1 (en) 2011-03-17 2012-09-20 Minerva Biotechnologies Corporation Method for making pluripotent stem cells
DK2723379T3 (en) 2011-06-23 2018-10-15 Biogen Int Neuroscience Gmbh ANTI-ALPHA SYNUCLEIN BINDING MOLECULES
US9701742B2 (en) * 2011-07-01 2017-07-11 The Trustees Of The University Of Pennsylvania Anti-properdin antibodies and uses thereof
BR112014027592A2 (pt) * 2012-05-09 2017-06-27 Koninklijke Philips Nv método para prover uma interface de rastreamento médico para comunicação entre pelo menos uma ferramenta de rastreamento de intervenção e um aplicativo de intervenção orientada por imagem (igi), interface de rastreamento médico, e produto de programa de computador
JP2015532303A (ja) 2012-10-04 2015-11-09 ノベルメド セラピューティクス，インコーポレーテッド 溶血性疾患を治療するための補体第２経路特異的抗体
TWI746426B (zh) 2014-11-16 2021-11-21 美商亞雷生物製藥股份有限公司 (S)-N-(5-((R)-2-(2,5-二氟苯基)-吡咯啶-1-基)-吡唑并[1,5-a]嘧啶-3-基)-3-羥基吡咯啶-1-甲醯胺硫酸氫鹽結晶型
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
KR20180021745A (ko) 2015-06-01 2018-03-05 록쏘 온콜로지, 인코포레이티드 암을 진단하고 치료하는 방법
EP3303387A2 (de) 2015-06-05 2018-04-11 Novartis AG Antikörper gegen knochenmorphogenetisches protein 9 (bmp9) und verfahren dafür
EP3322706B1 (de) 2015-07-16 2020-11-11 Array Biopharma, Inc. Substituierte pyrazol[1,5-a]pyridin-verbindungen als ret-kinasehemmer
KR20180037994A (ko) 2015-07-28 2018-04-13 오토노미, 인코포레이티드 TrkB 또는 TrkC 아고니스트 조성물 및 귀 병태의 치료 방법
TN2018000138A1 (en) 2015-10-26 2019-10-04 Array Biopharma Inc Point mutations in trk inhibitor-resistant cancer and methods relating to the same
MY198562A (en) * 2015-11-03 2023-09-05 Janssen Biotech Inc Antibodies specifically binding pd-1 and their uses
WO2017117384A1 (en) 2015-12-31 2017-07-06 Development Center For Biotechnology Anti-vegfr antibody and uses thereof
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
HUE068971T2 (hu) 2016-04-04 2025-02-28 Loxo Oncology Inc (S)-N-(5-((R)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-A]pirimidin-3-il) -3-hidroxipirrolidin-1-karboxamid folyékony készítményei
RS65988B1 (sr) 2016-04-04 2024-10-31 Loxo Oncology Inc Postupak lečenja pedijatrijskih karcinoma
SI3458456T1 (sl) 2016-05-18 2021-04-30 Loxo Oncology, Inc. Priprava (S)-N-(5-((R)-2-(2,5-difluorofenil) pirolidin-1-il) pirazolo (1,5-A) pirimidin-3-il)-3-hidroksipirolidin-1-karboksamida
CN109689027A (zh) 2016-06-29 2019-04-26 奥德纳米有限公司 甘油三酯耳用制剂及其用途
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
RU2766582C2 (ru) 2016-12-23 2022-03-15 Ремд Биотерапьютикс, Инк. Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1)
CN110267960B (zh) 2017-01-18 2022-04-26 阿雷生物药品公司 作为RET激酶抑制剂的取代的吡唑并[1,5-a]吡嗪化合物
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
EP4095161A1 (de) * 2017-03-15 2022-11-30 Tsinghua University Neuartige anti-trkb-antikörper
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
EP3648757A4 (de) * 2017-07-03 2020-11-25 Development Center for Biotechnology Anti-vegfr-antikörper und verwendungen davon
KR20250053967A (ko) 2017-08-22 2025-04-22 바이오젠 엠에이 인코포레이티드 항-베타 아밀로이드 항체를 함유하는 약제학적 조성물
WO2019067425A1 (en) 2017-09-26 2019-04-04 The Trustees Of The University Of Pennsylvania COMPOSITIONS AND METHODS FOR TREATING CARDIAC DISEASE BY REDIRECTED T-CELL IMMUNOTHERAPIES
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
TWI812649B (zh) 2017-10-10 2023-08-21 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
US11725045B2 (en) * 2017-10-13 2023-08-15 Mapp Biopharmaceutical, Inc. Anti-respiratory syncytial virus antibodies, methods of their generation and use
EP3700576A1 (de) 2017-10-26 2020-09-02 Array Biopharma Inc. Formulierungen eines makrocyclischen trk-kinaseinhibitors
TW201938169A (zh) 2018-01-18 2019-10-01 美商亞雷生物製藥股份有限公司 作為RET激酶抑制劑之經取代吡唑并[3,4-d]嘧啶化合物
WO2019143994A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
CN111971286B (zh) 2018-01-18 2023-04-14 阿雷生物药品公司 作为RET激酶抑制剂的取代的吡咯并[2,3-d]嘧啶化合物
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
CA3095366A1 (en) 2018-03-29 2019-10-03 Loxo Oncology, Inc. Treatment of trk-associated cancers
KR102653681B1 (ko) 2018-07-31 2024-04-03 록쏘 온콜로지, 인코포레이티드 (s)-5-아미노-3-(4-((5-플루오로-2-메톡시벤즈아미도)메틸)페닐)-1-(1,1,1-트리플루오로프로판-2-일)-1h-피라졸-4-카르복스아미드의분무-건조된 분산물 및 제제
ES2922314T3 (es) 2018-09-10 2022-09-13 Array Biopharma Inc Compuestos heterocíclicos condensados como inhibidores de cinasa RET
EP3898626A1 (de) 2018-12-19 2021-10-27 Array Biopharma, Inc. Substituierte pyrazolo[1,5-a]pyridin-verbindungen als inhibitoren von fgfr-tyrosinkinasen
WO2020131674A1 (en) 2018-12-19 2020-06-25 Array Biopharma Inc. 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer
CN114761036B (zh) 2019-09-23 2025-09-30 宾夕法尼亚大学董事会 与小鼠和人成纤维细胞激活蛋白(fap)交叉反应的抗犬成纤维细胞激活蛋白单克隆抗体
AU2020353000A1 (en) 2019-09-23 2022-04-07 The Trustees Of The University Of Pennsylvania Disrupting tumor tissues by targeting fibroblast activation protein (FAP)
CN117447602B (zh) * 2023-12-22 2024-03-19 北京索莱宝科技有限公司 猪IgM的抗体及其应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL95511A (en) * 1989-08-30 2000-10-31 Max Planck Gesellschaft Neurotrophin-3 a novel neurotrophic factor related to nerve growth and brain derived neurotrophic factor
CA2040099A1 (en) 1990-05-01 1991-11-02 Mariano Barbacid Tyrosine kinase negative trkb
US5364769A (en) * 1990-09-25 1994-11-15 Genentech, Inc. Nucleic acid encoding neurotrophic factor four (NT-4), vectors, host cells and methods of production
US5348856A (en) 1991-07-08 1994-09-20 E. R. Squibb & Sons, Inc. DNA encoding TRKC protein
EP0573904B1 (de) * 1992-06-08 2001-09-26 Takeda Chemical Industries, Ltd. Therapeutisches Agens für Neutropenie
US5855885A (en) * 1993-01-22 1999-01-05 Smith; Rodger Isolation and production of catalytic antibodies using phage technology
US5659791A (en) * 1993-04-26 1997-08-19 Microsoft Corporation Encapsulation of extracted portions of documents into objects
AU697142B2 (en) * 1993-11-23 1998-10-01 Genentech Inc. Protein tyrosine kinases named Rse
JP3442784B2 (ja) 1993-11-23 2003-09-02 ジェネンテク，インコーポレイテッド キナーゼ受容体活性化検定法
US5753225A (en) * 1993-12-03 1998-05-19 The Regents Of The University Of California Antibodies that mimic actions of neurotrophins
US5877016A (en) * 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
JPH07285912A (ja) * 1994-04-19 1995-10-31 Asahi Chem Ind Co Ltd 新規化合物ａｍ５２２１
WO1996036361A1 (en) * 1995-05-18 1996-11-21 The Regents Of The University Of Michigan Dna binding antibodies
CN1241944C (zh) * 1995-09-11 2006-02-15 协和发酵工业株式会社 抗人白介素－5受体α链的抗体
GB9525180D0 (en) 1995-12-08 1996-02-07 Univ Mcgill Design of hormone-like antibodies with agonistic and antagonistic fuctions
JP2001527402A (ja) 1997-04-25 2001-12-25 ジェネンテック，インコーポレーテッド Ｎｇｆ変異体
ES2316194T3 (es) 1998-10-28 2009-04-01 Cornell Research Foundation, Inc. Metodos para la regulacion de la angiogenesis y la integridad vascular utilizando los ligandos bdnf, nt-3 y nt-4.
US6656474B1 (en) * 1999-01-15 2003-12-02 Regeneron Pharmaceuticals, Inc. Methods of using a neurotrophin and its analogues for the treatment of gastrointestinal hypomotility disorders
DK1292680T3 (da) * 2000-06-22 2010-03-08 Genentech Inc Agonist-anti-TrkC monoklonale antistoffer

Also Published As

Publication number Publication date
US7615383B2 (en) 2009-11-10
US20040137513A1 (en) 2004-07-15
EP1292680B1 (de) 2009-10-21
CA2412494C (en) 2012-10-23
PL208113B1 (pl) 2011-03-31
HU228310B1 (en) 2013-03-28
JP2004500873A (ja) 2004-01-15
WO2001098361A9 (en) 2003-03-06
WO2001098361A2 (en) 2001-12-27
HUP0300841A3 (en) 2005-11-28
AU7142201A (en) 2002-01-02
CA2412494A1 (en) 2001-12-27
CN1447857A (zh) 2003-10-08
DK1292680T3 (da) 2010-03-08
HUP0300841A2 (hu) 2004-06-28
US20100003261A1 (en) 2010-01-07
KR20030036240A (ko) 2003-05-09
WO2001098361A3 (en) 2002-05-02
PL359926A1 (en) 2004-09-06
DE60140252D1 (de) 2009-12-03
IL153375A0 (en) 2003-07-06
BR0112272A (pt) 2003-05-06
KR100823764B1 (ko) 2008-04-21
US20070036794A1 (en) 2007-02-15
IL153375A (en) 2009-06-15
US20120045443A1 (en) 2012-02-23
US7384632B2 (en) 2008-06-10
AU2001271422B2 (en) 2005-12-22
NZ523105A (en) 2004-07-30
EP1292680A2 (de) 2003-03-19
CN100519749C (zh) 2009-07-29
MXPA02012602A (es) 2003-05-14

Similar Documents

Publication Publication Date Title
ATE446366T1 (de) Agonistische monoklonale antikörper gegen trkc
BR0011838B1 (pt) elemento de sela e estrutura de misturador estático.
NI200800032A (es) Reducción de célula b utilizando moléculas de unión específicas cd37 y cd20
TNSN08255A1 (en) Anti-mn antibodies and methods of using same
ATE515288T1 (de) Carboxy-amido-triazole zur lokalisierten behandlung von augenerkrankungen
TW200635608A (en) Aβ antibodies for use in improving cognition
TW200635607A (en) Humanized Aβ antibodies for use in improving cognition
DE69435307D1 (de) Bazillus Thuringiensis und dessen insektizide Proteine
EP1700120A4 (de) Marker für neuromyelitis optica
GEP20043349B (en) Methods of Controlling Cutworm Pests
SG166768A1 (en) Agonist anti-trkc antibodies and methods using same
EA200900425A1 (ru) Способ повышения толерантности растений
DE60033183D1 (de) Transplantatabstossung und damit verbundene zustände
WO2004083241A3 (en) Btc-interacting proteins and use thereof
BRPI0508084A (pt) método para o tratamento de um distúrbio neurológico, e, uso de meridamicina ou um sal do mesmo
ATE494307T1 (de) Neoplasma-spezifische antikörper und deren verwendungen
EP0929217A4 (de) Sordarinderivate
EP1007032A4 (de) 4-cyano-4-deformylsordarizin-derivate
ATE412010T1 (de) Selektive peptidische agonisten des vpac2- rezeptors
DE602006018461D1 (de) Galk1s als modifikatoren des pten/akt-wegs
EP1007031A4 (de) 4-cyano-4-deformylsordarinderivate
WO2004019880A3 (en) Aw755252-interacting proteins and use thereof
WO2005046617A3 (en) Compositions and methods for reducing microbial induced apoptosis
WO2003023048A3 (en) METHODS FOR DIAGNOSING AND TREATING DISEASES AND CONDITIONS ASSOCIATED WITH PROTEIN KINASE C$g(l)
Cvetkovic Diffusion and partitioning of small molecules in protein crystals

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties